In agreement with this hypothesis, we found that severe and critical COVID-19 patients in the INCOV cohort who reported one or more PASC symptoms had lower time-adjusted IL2-AIS scores compared to those reporting no PASC symptoms (Additional file 3: Fig. S3), which is consistent with more pronounced inflammatory responses in patients suffering from PASC. This evidence concerns the gene IL2 and COVID-19.